RxDoctor Payments DataLook up a doctor →

Malini Gupta, MD

Endocrinology, Diabetes & Metabolism · Memphis, TNNPI 1164626248

Payments from drug & device makers

$90,890in general payments, 2019–2025

Across 400 payments — averaging $227.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$45K
  • Chiesi USA, Inc.$28K
  • Ascendis Pharma Endocrinology Inc$7K
  • Novo Nordisk$3K
  • IBSA Pharma Inc.$2K
  • Eisai Inc.$2K
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$8,86010%
  • Speaking & faculty fees$63,66470%
  • Travel & lodging$7,1308%
  • Food & beverage$11,17012%
  • Education$650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,890 in reported general payments places this provider in the 75th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee

Medicare billing

Part B allowed, 2024
$154,204
Medicare patients
240
Services billed
6,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol82$102,326
OzempicSemaglutide55$95,840
JardianceEmpagliflozin60$88,336
JanuviaSitagliptin Phosphate52$71,070
JanumetSitagliptin Phos/Metformin Hcl40$53,157
TrulicityDulaglutide25$46,469
Xigduo XrDapaglifloz Propaned/Metformin30$35,839
Soliqua 100-33Insulin Glargine/Lixisenatide28$31,548
TradjentaLinagliptin22$28,131
RybelsusSemaglutide13$25,718
Bydureon BciseExenatide Microspheres15$23,645
Janumet XrSitagliptin Phos/Metformin Hcl15$18,783
MounjaroTirzepatide11$12,669
Tresiba Flextouch U-100Insulin Degludec16$11,879
SynjardyEmpagliflozin/Metformin Hcl12$11,677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet, Janumet Xr$39$143,010107 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$296$128,14494 claims
Novo NordiskOzempic, Rybelsus$2,510$121,55868 claims
AstraZenecaFarxiga$253$102,32682 claims
Lilly USA, LLCTrulicity, Mounjaro$265$59,13736 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$74$31,54828 claims
AbbVieSynthroid$412$8,33777 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$66$4,416363 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

Other endocrinology, diabetes & metabolism in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →